Analytical Data
-
基因名
GPIHBP1
- Application
-
别名
GPI-HBP1; High density lipoprotein-binding protein 1
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q8IV16
-
表达区间
Gln21~Gly151
-
分子量
21kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPIHBP1, or Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1, plays a critical role in lipid metabolism, particularly in the transport of triglyceride-rich lipoproteins. Research has indicated that GPIHBP1 functions as a bridge between lipoprotein lipase (LPL) and circulating triglyceride-rich lipoproteins, facilitating the hydrolysis of triglycerides in the bloodstream. Mutations in the GPIHBP1 gene have been linked to chylomicronemia syndrome, a rare disorder characterized by impaired lipid metabolism and significantly elevated triglyceride levels. These findings have underscored the importance of GPIHBP1 as a key player in lipid homeostasis and the regulation of cardiovascular health. The recombinant protein derived from GPIHBP1 has been the focus of numerous studies, aiming to better understand its structure-function relationship and potential therapeutic applications. By elucidating the mechanisms by which GPIHBP1 interacts with LPL and lipoproteins, researchers hope to develop targeted strategies for treating dyslipidemias and related cardiovascular diseases. The ongoing investigation into GPIHBP1 not only enhances our comprehension of lipid metabolism but also paves the way for novel interventions that could mitigate the risk of lipid-related disorders.
